Prostate Cancer Biomarker Market is Segmented By Assay Type ( Urine, Blood, Serum), By Category (Diagnostic prostate cancer biomarker, Prognostic prostate cancer biomarker, Stratification prostate cancer biomarker), By Region (North America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Prostate Cancer Biomarker Market Market Overview
180 pages report analyses the Prostate Cancer Biomarker Market Size, Analysis and Growth. The global prostate cancer biomarker Market is estimated at a high CAGR of 12.61% during the forecast period (2023-2030). Biomarkers are "chemicals" that can be used to detect both normal and pathological bodily processes. North America region is accounted for the largest market share in the global prostate cancer biomarker market. Competitive rivalry intensifies with BioVision Inc., QIAGEN N.V., Roche Diagnostics Limited and others operating in the market.
Prostate-specific antigen is one of the most well-known (PSA). For decades, the PSA test, which detects abnormally high PSA levels in the blood, has been used to screen for prostate cancer and possibly discover it early.
Prostate Cancer Biomarker Market Scope
|
Metrics |
Details |
|
Market CAGR |
12.61% |
|
Segments Covered |
By Assay Type, By Category and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Largest Market Share |
North America |
For More Insights Download Sample
Prostate Cancer Biomarker Market Trends
The factors driving the global prostate cancer biomarker market growth are the rising incidence of prostate cancer and the increasing awareness regarding diagnostic prostate cancer biomarker usage.
The rising incidence of prostate cancer is expected to drive the global prostate cancer biomarker market growth
Prostate cancer biomarker is the second most frequent cancer among men and the fourth most prevalent cancer in the general population. In 2018, there were 1.3 million new cases. According to GLOBOCAN 2018 estimates, 1,276,106 new cases of prostate cancer were reported worldwide in 2018, with developed nations having a greater prevalence.
Elevated plasmatic levels of prostate-specific antigen (PSA > 4 ng/mL), a glycoprotein usually expressed by prostate tissue, are used to detect many prostate malignancies. However, because men without cancer have been identified with increased PSA levels, a tissue biopsy is the gold standard for confirming the existence of malignancy. Diagnostic prostate cancer biomarker growth and progression are influenced by diet and physical exercise.
Dietary variables are primarily responsible for the reported global and ethnic disparities in prostate cancer biomarker incidence rates. Biomarkers are "chemicals" that can be used to detect both normal and pathological bodily processes. Hence, with prostate cancer's increasing incidence rate, the screening procedure using prostate biomarkers is also expected to increase.
Increasing awareness regarding the usage of prostate cancer biomarkers is expected to drive market growth in the forecast period
In men, prostate cancer biomarker is the second most common cause of cancer-related mortality. Several factors create severe challenges in creating viable therapeutic modalities and screening methods for cancer detection and treatment, despite the current improved understanding of the molecular pathways leading to advanced metastatic illness. Prostate cancer biomarker cells undergo a series of genetic and epigenetic changes that lead to abnormal proliferation, angiogenesis, apoptosis evasion, secondary site metastasis, and androgen independence.
These pro-oncogenic pathways and critical signalling molecules are currently being investigated at the molecular and cellular levels; with the application of this sophisticated technology to individual tumours, new markers identifying distinct tumour features in individual patients should be identified. The ability to characterise such indicators on a tailored level of analysis is likely to significantly impact how doctors diagnose early prostate cancer and intervene to reduce its prognosis.
Men have long been screened for prostate cancer using the prostate-specific antigen (PSA) biomarker. PSA cancer-specific sensitivity and present specificity challenges; nevertheless, a new generation of PCa biomarkers is emerging, consisting of serum-, urine-, and tissue-based assays that may enhance or eventually replace PSA testing. New genomic technologies have provided an additional interpretation of the specific patient's tumour biology, which has aided in identifying and developing these biomarkers. Several biomarkers are now commercially available with particular indications for illness diagnosis, prediction, prognosis, and therapy response.
The high cost of prostate cancer biomarkers is expected to hamper the market growth
Recent breakthroughs in targeted medicines have prompted hopes that using biomarkers in clinical settings will enhance patient outcomes while potentially saving money. Regardless of the cost-effectiveness of matching medicines, the cost-effectiveness of biomarkers remains unknown. According to the study, the average cost of treatment for a person with prostate cancer following diagnosis is around $2,800 per month. However, depending on whether the patient is insured or not, the sort of insurance or government aid one receives, and the precise type of treatment one requires, these prices can be greater or lower. Costs can also range depending on which country and the facilities one patient uses.
COVID-19 Impact on Global Prostate Cancer Biomarker Market
COVID-19 has affected the healthcare industry moderately. To stop its spread, government-imposed lockdown. People are fearful they may experience occupational effects and negative health from the COVID-19 pandemic. The stepwise procedure for localised prostate cancer starts with determining a diagnosis using a PSA level, imaging, and/or biopsy, and then moving on to deciding on a treatment plan. The recent appearance of Coronavirus Disease 2019 has had an impact on both diagnosis and treatment methods. The diagnosis tests were reduced during the pandemic due to the fear of COVID. This has moderately affected the global prostate cancer biomarker market due to limitations to avoid transmission of COVID.
Prostate Cancer Biomarker Market Segment Analysis
Based on Assay Type, the urine segment is expected to dominate the market growth
Because the prostate-specific antigen test lacks specificity for the identification of prostate cancer and can lead to unnecessary prostate biopsies, more specific biomarkers for prostate cancer and/or high-risk prostate cancer are needed. Urine is a viable source for developing novel prostate cancer. Prostate cancer is secreted into the prostatic secretions and eventually into the urine. After prostate modification, urine is enriched with Diagnostic prostate cancer biomarker biomarkers, such as prostate cancer cells, DNAs, RNAs, proteins, and other tiny molecules.
The urine c prostate cancer antigen 3 test is the first RNA-based urinary marker approved by the Food and Drug Administration. It aids in the detection of prostate cancer during repeat biopsy. The SelectMDx test detects DLX1 and HOXC6 messenger RNA in urine after prostate massage and aids in diagnosing high-risk prostate cancer on prostate biopsy. Exosomes are extracellular vesicles that range in size from 30 to 200 nanometers in diameter and are released by various cell types.
Exosomes generated from urinary prostate cancer contain RNAs and proteins specific to prostate cancer (e.g., PCA3 and TMPRSS2-ERG), and could be useful for finding new biomarkers. The ExoDx Prostate test is a commercially available test that detects three genes in urine exosomes (PCA3, ERG, and SPDEF). Thanks to advances in comprehensive analysis, several urine biomarkers have been discovered (microarray, mass spectrometry, and next-generation sequencing). Non-invasive urine indicators can aid in the choice to do a prostate biopsy or the formulation of a treatment plan.
PCA3 has been the first true urine biomarker for a prostate cancer biomarker, thanks to FDA approval. Investigators have developed a second urine test based on TMPRSS2: erg fusion using the same technology.
Prostate Cancer Biomarker Market Geographical Share
North America region is accounted for the largest market share in the global prostate cancer biomarker market
The market growth in this region is expected to dominate owing to the rising incidence of prostate cancer, awareness about the disease and increasing diagnostic procedures for screening prostate cancer.
According to CDC, prostate cancer is a disease that affects all males. prostate cancer affects roughly 13 out of every 100 American men at some point in their lives, and 2 to 3 men die from it. Every September in North America, health experts, health advocates, and those concerned with men's prostate health and Diagnostic prostate cancer biomarker observe National Prostate Health Month (NPHM), also known as National prostate cancer Awareness Month.
Prostate Cancer Biomarker Companies & Competitive Players
The global prostate cancer biomarker market is highly competitive with increasing demand for screening procedures for prostate cancer and increasing diagnostic procedures.
Some major key players in the global prostate cancer biomarker Market are BioVision Inc., QIAGEN N.V., Roche Diagnostics Limited, Beckman Coulter Inc and Myriad Genetics, Sanofi-Aventis, Pfizer Inc, MDx Health
Beckman Coulter Inc
Overview: Beckman Coulter Inc, as a company, is dedicated to enhancing healthcare for all people by leveraging the power of science, technology, and their employees' enthusiasm and creativity to improve the diagnostic laboratory's role in improving healthcare outcomes. The company’s diagnostic systems are used in hospitals, reference laboratories, and physician offices all over the world for complicated biomedical testing.
Since 2011, Beckman Coulter has been an operating company of Danaher Corporation, with headquarters in Brea, Calif., and more than 11,000 global employees dedicated to making the world a healthier place.
Product Portfolio: Beckman Coulter Life Sciences is a well-known, global provider of instruments to assist researchers and manufacturers in improving their productivity. Centrifuges. Counters and analyzers for particles, liquid handlers that are fully automated. Flow cytometers are instruments that measure the amount of blood in the body—reagents for genomic analysis.
Key Development: On February 1st, 2021, Beckman Coulter released the DxH 560 AL, a tabletop analyzer designed to help small and mid-sized laboratories overcome time and resource restrictions. The DxH 560 AL provides results in 60 seconds or less. It is perfect for difficult-to-draw patients (infants, cancer, and the elderly) because it only requires a 17-litre sample – less than a drop of blood, making it one of the smallest aspiration volumes available.
The global prostate cancer biomarker market report would provide access to an approx. 37 market data table, 36 figures and 180 pages.
